From: How to use thionamide anti-thyroid drug in the young– what’s new?
• The relationship between ATD duration beyond 5 years and likelihood of relapse needs to be established in greater detail. | |
• The baseline immune and genetic factors that may impact on the likelihood of remission need to be explored in more detail. This may help to predict outcome. | |
• Patients can potentially be stratified as at low or high risk of an adverse reaction to ATD including agranulocytosis with associated alterations in surveillance program. | |
• The potential role of long-term iodine therapy needs to be explored in more detail. | |
• The role of existing and novel immunomodulatory agents needs to be explored. |